Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CorMedix Inc.
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Keeping Track: Novel Oncologics Submitted By Taiho, ImmunoGen, Y-mAbs; US FDA Declines Akebia’s Vadadustat
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Medical Devices
- Specialty Pharmaceuticals